Sayronem

The drug Sayronem (manufacturer - Simpex Pharma Pvt. Ltd, India) is an antibiotic of the carbapenem (beta-lactam) group. Other trade names of antimicrobial agents of this pharmacological group: Meronem, Meropenem, Ipinem, Doriprex, Doripenem, Propinem, etc.

Indications Sayronem

Sayronem (active ingredient - meropenem) is used in the treatment of severe forms of inflammatory diseases caused by microbes resistant to other antibiotics (penicillin, ampicillin, etc.). These diseases include pneumonia (including those complicated by nosocomial infection); cystic fibrosis and chronic infections of the bronchi and lungs; urological infectious pathologies ( pyelonephritis, including purulent-septic forms); severe forms of infection of the abdominal cavity and pelvic organs ( appendicitis, peritonitis ); gynecological infections (including postpartum); polymicrobial infections of soft tissues and skin ( erysipelas, impetigo ); meningitis; bacterial blood poisoning ( sepsis and septicemia).

Release form

The drug is available in the form of powder in vials (500 mg and 1000 mg) for the preparation of a solution for intravenous injections.

Pharmacodynamics

The pharmacological action of Cyronem is based on the ability of the active substance of the drug to quickly penetrate the cell membranes of gram-positive and gram-negative aerobic bacteria (pneumococci, gonococci, meningococci, staphylococci) and anaerobic bacteria (Aeromonas caviae, Klebsiella ozaenae, Enterobacter spp, Salmonella spp, Serratia marcescens, Shigella sonnei and many others).

As a result of the increased antimicrobial activity of the drug, the biosynthesis process in bacterial cells is inhibited by binding specific proteins of their cell wall (beta-lactams). This enzyme makes bacteria resistant to most antibiotics, but Sayronem neutralizes beta-lactamase, which leads to the destruction (lysis) of the cells of pathogenic microorganisms.

This is the reason for the pronounced antimicrobial effect of Sayronem against pathogens of many diseases. However, such types of bacteria as Xanthomonas maltophilia, Enterococcus faecium, as well as strains of Staphylococcus spp, resistant to the antibiotic methicillin, show resistance to Sayronem.

Pharmacokinetics

The drug is administered intravenously or intramuscularly and penetrates well into most tissues and body fluids (blood plasma, cerebrospinal fluid of patients with bacterial meningitis, etc.). It is metabolized to form one microbiologically inactive metabolite. When injected into a vein, the half-life of the drug (T1/2) in adults (in the absence of kidney pathology) is one hour, with intramuscular injection - one and a half hours.

Approximately 2% of the dose is bound to plasma proteins, about 70% is excreted unchanged in the urine within 12 hours. In lactating women, the drug is excreted in breast milk.

Dosing and administration

For adults, a single intravenous dose is from 500 mg to 2 g. The frequency of administration of the drug, as well as the duration of the course of treatment, are determined depending on the indications and severity of the disease. The dosage for children weighing up to 50 kg is 10-12 mg per kilogram, with a body weight over 50 kg - doses similar to adults. The drug is administered every 8 hours.

For intramuscular administration, the dose for adults is 500 mg every 8 hours, for elderly patients - every 12 hours.

[ 2 ]

Use Sayronem during pregnancy

The use of Sayronem during pregnancy and lactation is permitted only after comparing the expected therapeutic benefit for the mother and the possible risk to the fetus or child. The use of Sayronem for the treatment of children under 3 months of age is not recommended.

Contraindications

Contraindications to the use of Sayronem are of the nature of “special instructions”, which include:

• hypersensitivity to penicillins and antibiotics of the carbapenem group (beta-lactams). In this case, there is a risk of developing complications of antibiotic treatment in the form of specific dysbacteriosis and inflammatory bowel disease (pseudomembranous enterocolitis);
• the presence of liver disease and lower respiratory tract diseases caused by Pseudomonas aeruginosa;
• In case of liver pathologies, it is necessary to monitor the level of bilirubin and liver transaminases (ALT and AST).

Side effects Sayronem

Side effects of the drug Sayronem may manifest as headache; unpleasant sensations such as burning, crawling, numbness (paresthesia);

Pain in the epigastric region; nausea, vomiting, diarrhea; skin itching, rash, urticaria.

Possible increase (reversible) in the level of bilirubin, transaminases, alkaline phosphase (ALP) and lactate dehydrogenase (LDH) in the blood; decrease in hemoglobin level; increase in the concentration of urea in plasma.

Renal dysfunction (hypercreatininemia), hematuria and vaginal candidiasis are also possible. Local reactions include inflammation, phlebitis, thrombophlebitis, pain, and swelling at the injection site.

[ 1 ]

Overdose

Cases of overdose with Sayronem have not been reported in clinical practice.

Interactions with other drugs

As a result of studying the interaction of Sayronem with other drugs, the following conclusion was made: do not recommend using Sayronem in combination therapy with uricolytic drugs (probenecid, benemid, santuril). These anti-gout drugs can delay the excretion of other drugs by the kidneys, increasing their concentrations in the blood plasma.

[ 3 ], [ 4 ]

Storage conditions

Storage conditions for the drug: in a dry and dark place, at a temperature not exceeding +30°C.

Shelf life

The shelf life of the drug is 2 years from the date of manufacture.